CLINICAL_TRIALS
ClinicalTrials.gov record update
Exploratory Efficacy and Safety Study of PD-1 Inhibitor Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT04371796
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:37:43.494822+00:00
- Published At
- 2020-05-01T00:00:00+00:00
- Record Updated At
- 2020-05-01
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Lung Diseases", "Neoplasms", "Respiratory Tract Diseases", "Thoracic Neoplasms", "Non-small-cell Lung Cancer"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2020-05-01"- protocolSection.identificationModule.nctId
"NCT04371796"- protocolSection.identificationModule.officialTitle
"Exploratory Efficacy and Safety Study of PD-1 Inhibitor Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC"- protocolSection.statusModule.overallStatus
"UNKNOWN"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.